All Posts Tagged With: "MDT"
(STJ) St. Jude Medical Build on Alliance with Abbott Laboratories
St. Jude Medical Inc. (STJ) recently disclosed its decision to build on its mutual agreement with Abbott Laboratories (ABT) by revealing...
(IART) Integra LifeScience Holdings Corporation Earns FDA Nod for Spine Device
Global provider of surgical implants and medical instruments, Integra LifeScience Holdings Corporation (IART) recently received the 510(k) clearance from the US Food and Drug Administration...
(STJ) St. Jude Beats The Street – Raises Guidance
St. Jude Medical, Inc. (STJ), a large-cap medical devices and technology development company, reported first quarter fiscal 2012 adjusted earnings of 86 cents beating the Zacks Consensus Estimate of 83 cents...
(MDT) MedTech Industry Stock Outlook – March 2012 – Zacks Analyst Interviews
Last year proved to be challenging for medical technology (“MedTech”) stocks given the exigent economic conditions and the precarious healthcare environment. The performance of incumbent players was hamstrung by several macro issues, including sustained price and procedure...
(MDT) MedTech Industry Stock Outlook – March 2012 – Industry Outlook
Last year proved to be challenging for medical technology (“MedTech”) stocks given the exigent economic conditions and the precarious healthcare environment. The performance of incumbent players was hamstrung by several macro issues, including sustained price and procedure...
(GB) Greatbatch Buying NeuroNexus
Medical technology company Greatbatch (GB) is acquiring Michigan-based implantable medical device design firm NeuroNexus Technologies for roughly $12 million. The deal includes assumption of debt and future...
(STJ) St. Jude Medical Fourth Quarter 2011 Earnings Scorecard
Medical devices major St. Jude Medical’s (STJ) fourth-quarter 2011 adjusted earnings per share of 86 cents beat the Zacks Consensus Estimate by a couple of cents and exceeded the year-ago earnings of 75...
(STJ) New Year Bets from MedTech
Picking the right stock is never easy, especially in a difficult and volatile market. There are thousands of stocks to choose from and many investors eventually end up boiling the ocean.
The U.S. economy continues to be cramped by a spate of headwinds including a still...
(ALNY) Alnylam States Preclinical Data
Alnylam Pharmaceuticals Inc (ALNY) recently announced pre-clinical data from a trial evaluating its pipeline candidate ALN-HTT for the treatment of Huntington’s disease (HD). ALN-HTT is a novel therapeutic...
(STJ) Christmas Gift for the Ailing Heart
Wilson Greatbatch, the self-professed “humble tinkerer” and a trailblazer in medical technology, invented the first implantable cardiac pacemaker in 1958 which kept the rhythm of millions of heartbeats and preserved countless lives across the planet.
A couple...
(ALNY) Alnylam Pharmaceuticals Analyst Still Bullish
We have maintained an Outperform rating on Alnylam Pharmaceuticals, Inc (ALNY) with a target price of $8.25 per share following appraisal of third quarter 2011 results.
Alnylam Pharmaceuticals Inc....
(BSX) Boston Scientific Corporation Grows US Cardiac Rhythm Management Portfolio
Boston Scientific Corporation’s (BSX) Cardiac Rhythm Management (CRM) should record higher sales with the US Food and Drug Administration (FDA) approving Incepta, Energen and Punctua cardiac resynchronization...
(ALNY) Alnylam Pharmaceuticals Completes Trial Enrollment
Alnylam Pharmaceuticals Inc. (ALNY) recently announced it has completed enrollment in a mid-stage study of its pipeline candidate ALN-RSV01, an RNA interference technology (RNAi) therapeutic being studied...
(ZOLL) ZOLL Medical’s AutoPulse Tapped by WSPR Szczecin
Resuscitation devices maker ZOLL Medical (ZOLL) said that its new AutoPulse Plus cardiac support pumps has been bought by WSPR Szczecin, the biggest emergency service operator in Poland. The Polish entity...
(MDT) Medtronic 2012 Second Quarter Earnings Scorecard
The announcement of Medtronic’s (MDT) second quarter fiscal 2012 results, as on November 22, 2011, has led analysts to revise their estimates lower for the third quarter although the situation improves...
(ALNY) Alnylam Pharmaceuticals Reveals ALNTTR01 Trial Data
Alnylam Pharmaceuticals Inc. (ALNY) recently presented data from an early stage study of its pipeline candidate ALN-TTR01 at a scientific conference in Japan. ALN-TTR01 is a systemically delivered RNA interference...
(MDT) Medical Technology Industry Stock Outlook – November 2011 – Industry Outlook
The performance of incumbent players in the MedTech industry continued to be hamstrung by a spate of macro issues (including sustained price and procedure volume pressures) in the September quarter. The prevailing macroeconomic factors, pricing headwinds, austerity measures,...
(EW) Edwards Lifesciences Earns FDA OK on Trial Enrollment
Recently, Edwards Lifesciences Corporation (EW) received conditional approval from the US Food and Drug Administration for enrollment of a certain group of patients in the PARTNER II trial. The trial is studying...
(GB) Greatbatch Analyst Raises Shares to Outperform
We upgrade our recommendation on Greatbatch (GB) to Outperform following its impressive third-quarter 2011 results. Adjusted earnings of 41 cents for the quarter outstripped the Zacks Consensus Estimate of...
(GB) Greatbatch Third Quarter 2011 Earnings Helped By Medical Business
Greatbatch’s (GB) third-quarter fiscal 2011 adjusted (excluding one-time items) earnings per share of 41 cents outpaced both the Zacks Consensus Estimate and the year-ago adjusted earnings of 34 cents.
Profit...
(EW) Edwards Lifesciences 2011 Fourth Quarter Earnings Scorecard
The announcement of Edwards Lifesciences’ (EW) third quarter fiscal 2011 results as on October 19, 2011, has led analysts to revise their estimates lower for the fourth quarter and fiscal 2011.
Third...
(EW) Edwards Lifesciences Corporation Earnings Preview
Edwards Lifesciences Corporation (EW) is scheduled to release its third quarter fiscal 2011 results on Wednesday, October 19, 2011 after the market closes.
The company is expected to earn 39 cents per...
(ALNY) Alnylam Pharmaceuticals Announces Pipeline Progress
Recently, Alnylam Pharmaceuticals Inc. (ALNY) announced the commencement of an early-stage stage study (n~32) of its RNAi (RNA (Ribo Nucleic Acid) interference) therapeutic program ALN-PCS for treating patients...
(EW) Edwards Lifesciences Announces Share Buyback
Edwards Lifesciences Corporation (EW) recently announced a new share repurchase program worth $500 million. At the end of the second quarter of fiscal 2011, the company was left with $240 million of authorization....
(EW) Edwards Lifesciences Sapien Under Centers for Medicare & Medicaid Services NCA
Edwards Lifesciences (EW) received a major setback as the Centers for Medicare & Medicaid Services (CMS) decided to initiate a National Coverage Analysis (NCA) of transcatheter aortic valve replacement...
(BSX) Boston Scientific Launches Coyote Balloon Catheter
Boston Scientific Corporation (BSX) strengthened its Peripheral Interventions portfolio with the launch of Coyote Balloon catheter (0.014 inch) to treat patients undergoing peripheral angioplasty procedures...
(MDT) Medtronic Grows Spinal Portfolio
Leading medical devices player, Medtronic’s (MDT) TSRH Spinal System has received 510 (k) clearance from the US Food and Drug Administration (FDA) to treat adolescent idiopathic scoliosis (AIS) with pedicle...
(MDT) Medical Devices Stock Outlook – Sept. 2011 – Industry Outlook
June quarter results mostly mirror the preceding quarter as a host of macro headwinds (including price and procedure volume pressures) continued to haunt the MedTech industry and weighed on the performance of the incumbent players. Although a number of these issues are expected...
(ALNY) Alnylam Pharmaceuticals Analyst Maintains Neutral Rating on Shares
We have maintained a Neutral rating on Alnylam Pharmaceuticals, Inc (ALNY) with a target price of $7.00 per share.
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapeutics...
(GILD) Take Advantage of the Fire Sale in Healthcare
by Marc Lichtenfeld, Investment U Senior Analyst
Wednesday, August...